Navigation Links
BioMS Medical's relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
Date:11/7/2007

Toronto Stock Exchange Symbol: MS

EDMONTON, Nov. 7 /PRNewswire-FirstCall/ - BioMS Medical Corp. (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that the independent Data Safety Monitoring Board (DSMB) for the Company's phase II MINDSET-01 trial of MBP8298 in patients with relapsing-remitting MS has completed a safety analysis and recommended that the trial continue as per the protocol.

This was the second of several regularly scheduled reviews by the DSMB that will occur over the duration of the trial. The purpose of the DSMB is to provide objective, independent safety monitoring of the trial.

MINDSET-01 Trial

----------------

The MINDSET-01 phase II, double-blind, placebo-controlled trial is designed to evaluate the safety and efficacy of MBP8298 in patients with relapsing-remitting MS. The fifteen month trial is fully enrolled with 218 patients at 24 sites in 6 countries. The objectives of the study are to demonstrate safety and efficacy of MBP8298 versus placebo as measured by relapse rate, MRI activity and disease progression.

About BioMS Medical Corp.

-------------------------

BioMS Medical is a biotechnology company engaged in the development and commercialization of novel therapeutic technologies. BioMS Medical's lead technology, MBP8298, is for the treatment of multiple sclerosis and is being evaluated in two pivotal phase III clinical trials for secondary progressive MS patients, MAESTRO-01 in Canada and Europe and MAESTRO-03 in the United States. It additionally is being evaluated for relapsing remitting MS patients in a Phase II trial in Europe entitled MINDSET-01. For further information please visit our website at http://www.biomsmedical.com.

This press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These
'/>"/>

SOURCE BioMS Medical Corp.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. BioMS Medical announces its intention to renew a normal course issuer bid
2. BioMS Medical to present at BioContact 2007
3. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
4. Amnis Announces the Release of Multiple Upgrades to the ImageStream(R) System
5. Phase 2 Data Show Daclizumab Significantly Reduced Multiple Sclerosis Lesions in Patients Receiving Interferon Beta Therapy
6. Bioponic Phytoceuticals to Roll Out Multiple Products to 1,000 Major Health Food Stores in the Western United States
7. Actelion Announces Multiple Presentations on Tracleer(R) and the REVEAL Registry at CHEST 2007
8. Video: New Survey Finds Technology Plays a Critical Role in Lives of People with Multiple Sclerosis, Yet Many Are Not Using it to Overcome Disease-Related Challenges
9. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
10. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
11. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... 2013 Venaxis, Inc. (Nasdaq:   APPY), an ... FDA clearance and commercializing its rapid, protein biomarker-based appendicitis ... an underwritten public offering of 10,000,000 shares of its ... of its common stock at an exercise price of ... of $1.25 per share and related warrant.  Venaxis has ...
(Date:5/23/2013)... 23, 2013 Patheon Inc ., ... to the global pharmaceutical industry, will host a complimentary ... to Testing” on Tuesday, June 4, 2013 at 11 ... are required to comply with regulations for cleaning validation. ... limited scientific underpinning and little evaluation of risk. ...
(Date:5/23/2013)... 23, 2013 PI’s new LPS-24 ... provide 15 mm travel range with closed-loop sensor ... dimensions make these new positioners the ideal choice ... vacuum rated version is also available. , ... datasheets can be found at: , http://www.physikinstrumente.com/en/products/prdetail.php?sortnr=1000745&prw-lps24 ...
(Date:5/23/2013)... May 23, 2013 BioTrends Research Group, ... firms for specialized biopharmaceutical issues, finds that, unaided, ... disease specialists reported that in the past six ... delaying treatment) in anticipation of the next generation ... ago, when only 6 percent reported that they ...
Breaking Biology Technology:Venaxis Announces Pricing of Offering of Common Stock and Warrants 2Venaxis Announces Pricing of Offering of Common Stock and Warrants 3Patheon to Present on “Cleaning Validation: Science, Risk and Novel Approaches to Testing” 2Precision Positioning System Uses Miniaturezed Piezo Linear Motor: LPS-24 Linear Stage by PI 2The Majority of Physicians that Treat Hepatitis C Virus (HCV) Have Begun "Warehousing" and Preparing Their HCV Patients for the Next Generation of HCV Treatments 2The Majority of Physicians that Treat Hepatitis C Virus (HCV) Have Begun "Warehousing" and Preparing Their HCV Patients for the Next Generation of HCV Treatments 3
... July 13 Instrumentation Laboratory (IL) today announced it ... recipients at the upcoming Congress for the International Society ... Meeting for the American Association for Clinical Chemistry (AACC), ... IL on July 19-23 respectively. Launched in July ...
... , ROCKVILLE, Md. , July 13 ... PARADIGM trial, a Phase 2 clinical study evaluating MGAWN1, ... with suspected central nervous system infection due to West ... company that develops immunotherapeutics to treat autoimmune disorders, cancer ...
... SYDNEY, July 12 /PRNewswire-Asia/ -- Pharmaxis (ASX: ... to voluntarily de-list from the Nasdaq Global,Market ("Nasdaq"). , ... review of the demand from existing and,potential international investors ... on Nasdaq and the volume of Pharmaxis ADS trading,in ...
Cached Biology Technology:Instrumentation Laboratory to Announce 'Passion & Results' Award Winners 2Instrumentation Laboratory to Announce 'Passion & Results' Award Winners 3MacroGenics Announces the Initiation of a Phase 2 Clinical Trial to Evaluate the Safety and Efficacy of Monoclonal Antibody MGAWN1 in Subjects with Suspected Central Nervous System Infection Due to West Nile Virus 2MacroGenics Announces the Initiation of a Phase 2 Clinical Trial to Evaluate the Safety and Efficacy of Monoclonal Antibody MGAWN1 in Subjects with Suspected Central Nervous System Infection Due to West Nile Virus 3MacroGenics Announces the Initiation of a Phase 2 Clinical Trial to Evaluate the Safety and Efficacy of Monoclonal Antibody MGAWN1 in Subjects with Suspected Central Nervous System Infection Due to West Nile Virus 4Pharmaxis to Voluntarily De-List from Nasdaq 2
(Date:5/24/2013)... Frontiers, one of the world,s largest and fastest growing ... journal, Frontiers in Physics . , A broad ... will provide an open-science and interactive web platform ... rigorously peer-reviewed articles. , Frontiers, real-time and interactive ... range of article types. With an average of three ...
(Date:5/24/2013)... After studying noise in one French Quarter neighborhood ... levels exceeded municipal ordinances, Annette Hurley, PhD, Assistant Professor ... and Eric Arriaga, a third-year LSUHSC doctor of audiology ... their own hearing health. Their case study is published ... Hearing Practice Management ., "An important part of an ...
(Date:5/23/2013)... be the world,s most popular fruit, can be made ... purple GM varieties. , "Working with GM tomatoes ... addition of a specific compound, allows us to pinpoint ... Cathie Martin from the John Innes Centre. , The ... flavour, health and shelf life characteristics because even higher ...
Breaking Biology News(10 mins):Frontiers launches new open-access journal in physics 2Frontiers launches new open-access journal in physics 3Please do try this at home 2The world's favorite fruit only better-tasting and longer-lasting 2
... have discovered that chickens raised for meat can choose ... towards themselves or their eggs. , That phenomenon of ... figure out how to deal with less productive hens ... own bodies. "They like to be a little bit ...
... of Michigan State University researchers will use a $4 ... the functions of genes in a plant - research ... and agriculture. , In a collaborative effort spanning several ... 4,400 nuclear genes from the Arabidopsis plant. Arabidopsis is ...
... regulates the body's main biological clocks also may play ... Southwestern Medical Center have found. , The Clock gene ... and wakefulness, body temperature, hormone levels, blood pressure and ... of the brain's reward system. , UT Southwestern researchers ...
Cached Biology News:What comes first…the chicken, the egg, or the bad attitude? 2MSU researchers receive $4 million grant to uncover gene functions 2Gene controlling circadian rhythms linked to drug addiction 2
... Certified USDA Research Registered OLAW Assured AAALAC ... AALAS Certified Technicians Documentation ... Upon Request Focus CRP is ... your custom immunology service needs. We ...
...
Applications: Western blotting ...
...
Biology Products: